Search

Your search keyword '"Copelan, Edward A."' showing total 1,117 results
Start Over Author "Copelan, Edward A."
1,117 results on '"Copelan, Edward A."'

202. Peripheral Immune Profile and Minimal Residual Disease (MRD) Burden Following Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)

Author

Foureau, David, primary, Zhang, Qing, additional, Cogdill, Tammy D, additional, Wynn, Adina S, additional, Steuerwald, Nury M., additional, Druhan, Lawrence J., additional, Guo, Fei, additional, Rigby, Katherine, additional, Madden, Kyle L, additional, Symanowski, James T, additional, Avalos, Belinda R., additional, Copelan, Edward A., additional, Usmani, Saad Z, additional, and Bhutani, Manisha, additional

Published
2016
Full Text
View/download PDF

204. MYC Pathway Upregulation Identified in Non-Responders to Hypomethylating Agents and Presents a Therapeutic Target in Acute Myeloid Leukemia

Author

Ragon, Brittany Knick, Templeton, Margaret D., Seegers, Sara L., Chen, Jenny, Yang, Hsih-Te, Knight, Thomas G., Ai, Jing, Copelan, Edward A., Avalos, Belinda, Steuerwald, Nury M., Jin, Jian, Wang, Gang Greg, Park, Steven I., Patel, Jai N., Grunwald, Michael R., and Druhan, Lawrence J.

Abstract

Background:In the current era of acute myeloid leukemia (AML) management, hypomethylating agents (HMAs) remain as the backbone of combination regimens for front-line treatment of elderly or unfit patients (pts) and/or as salvage therapy in relapsed/refractory pts. Data on biological predictors of HMA response are limited. Our previous work explored cytidine deaminase (CDA), known to inactivate HMAs, and nucleophosmin 1 (NPM1), determined by core pathway analysis to indirectly influence CDA expression. No clear correlation was identified in pt samples between CDA protein expression and NPM1 status or response, and pharmacogenomic analysis showed no CDAsingle nucleotide polymorphisms were predictive of response to HMAs. We aimed to expand prior findings using RNA sequencing (RNA seq) and gene set enrichment analysis (GSEA) to identify gene signatures predictive of HMA response and propose potential therapeutic targets.

Published
2023
Full Text
View/download PDF

205. Neighborhood Disadvantage Is Associated with Inferior Overall Survival for Acute Myeloid Leukemia Patients Treated with Standard Intensive Induction

Author

Ragon, Brittany Knick, Boselli, Danielle, Bose, Rupali, Begley, Stephanie, Aguiar, Melissa, Blackley, Kris, Shah, Nilay, Chojecki, Aleksander L., Sanikommu, Srinivasa Reddy, Pang, Yifan, Ai, Jing, Avalos, Belinda, Copelan, Edward A., Knight, Thomas G., and Grunwald, Michael R.

Abstract

Background:Identifying biologic and socioeconomic contributors to disparities in outcomes is critical for the management of acute myeloid leukemia (AML). Prior studies in AML revealed that Black patients (pts) have inferior survival compared to White pts, with more striking disparity for Black pts aged <60. We previously explored our large and diverse AML cohort from urban and large rural areas and did not identify inferior survival for pts with self-reported Black race or Hispanic ethnicity. Although no surrogates for social determinants of health (SDOH) or insurance status were recognized as contributing to survival differences, oncology nurse navigation (ONN) was associated with a survival benefit, with no significant difference in access to ONN among racial or ethnic groups. To further evaluate socioeconomic drivers of disparities in this population supported by ONN, we aim to use the Area Deprivation Index (ADI) to determine the impact of neighborhood disadvantage on survival in AML.

Published
2023
Full Text
View/download PDF

207. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Author

Shaffer, Brian C., primary, Ahn, Kwang Woo, additional, Hu, Zhen-Huan, additional, Nishihori, Taiga, additional, Malone, Adriana K., additional, Valcárcel, David, additional, Grunwald, Michael R., additional, Bacher, Ulrike, additional, Hamilton, Betty, additional, Kharfan-Dabaja, Mohamed A., additional, Saad, Ayman, additional, Cutler, Corey, additional, Warlick, Erica, additional, Reshef, Ran, additional, Wirk, Baldeep Mona, additional, Sabloff, Mitchell, additional, Fasan, Omotayo, additional, Gerds, Aaron, additional, Marks, David, additional, Olsson, Richard, additional, Wood, William Allen, additional, Costa, Luciano J., additional, Miller, Alan M., additional, Cortes, Jorge, additional, Daly, Andrew, additional, Kindwall-Keller, Tamila L., additional, Kamble, Rammurti, additional, Rizzieri, David A., additional, Cahn, Jean-Yves, additional, Gale, Robert Peter, additional, William, Basem, additional, Litzow, Mark, additional, Wiernik, Peter H., additional, Liesveld, Jane, additional, Savani, Bipin N., additional, Vij, Ravi, additional, Ustun, Celalettin, additional, Copelan, Edward, additional, Popat, Uday, additional, Kalaycio, Matt, additional, Maziarz, Richard, additional, Alyea, Edwin, additional, Sobecks, Ron, additional, Pavletic, Steven, additional, Tallman, Martin, additional, and Saber, Wael, additional

Published
2016
Full Text
View/download PDF

208. Filgrastim Plus Fixed-Dose Plerixafor is Cost-Effective in Peripheral Blood Hematopoietic Cell Mobilization in Patients with Multiple Myeloma

Author

Chow, Eric, primary, Fasan, Omotayo, additional, Usmani, Saad, additional, Jacobs, Ryan, additional, Sun, Danyu, additional, Plesca, Dragos, additional, Trivedi, Jigar S., additional, Riddagh, Cindy, additional, Feild, Donna J., additional, Avalos, Belinda, additional, and Copelan, Edward A., additional

Published
2016
Full Text
View/download PDF

209. Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes

Author

Muffly, Lori, primary, Pasquini, Marcelo C., additional, Martens, Michael, additional, Brazauskas, Ruta, additional, Zhu, Xiaochun, additional, Adekola, Kehinde, additional, Aljurf, Mahmoud D., additional, Artz, Andrew S., additional, Bajel, Ashish, additional, Ballen, Karen K., additional, Battiwalla, Minoo, additional, Beitinjaneh, Amer, additional, Cahn, Jean-Yves, additional, Carabasi, Matthew, additional, Chen, Yi-Bin, additional, Chhabra, Saurabh, additional, Ciurea, Stefan O., additional, Copelan, Edward A., additional, D'Souza, Anita, additional, Edwards, John, additional, Freytes, Cesar O., additional, Fung, Henry C., additional, Gale, Robert Peter, additional, Giralt, Sergio A., additional, Hashmi, Shahrukh K., additional, Hematti, Peiman, additional, Hildebrandt, Gerhard C., additional, Ho, Vincent T., additional, Jakubowski, Ann A., additional, Lazarus, Hillard M., additional, McCarthy, Philip L., additional, Olin, Rebecca L., additional, Olsson, Richard, additional, Rezvani, Andrew, additional, Rizzieri, David A., additional, Seftel, Matthew, additional, Seo, Sachiko, additional, Sorror, Mohamed L., additional, Szer, Jeffrey, additional, and Wood, William A., additional

Published
2016
Full Text
View/download PDF

211. Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Utilizing a Reduced Fixed Dose of Plerixafor and a Unique Mobilization Algorithm is Feasible and Maximizes Day 1 Collection Yield

Author

Fasan, Omotayo, primary, Chow, Eric, additional, Usmani, Saad, additional, Trivedi, Jigar S., additional, Plesca, Dragos, additional, Croom, Margaret, additional, Lee, Carlos G., additional, Carter, Samantha M., additional, Bhutani, Manisha, additional, Avalos, Belinda, additional, and Copelan, Edward A., additional

Published
2016
Full Text
View/download PDF

212. Cytomegalovirus Infection in T Cell Replete Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide- A Single Center Experience

Author

Shahid, Zainab, primary, Symanowski, Jim, additional, Lestrange, Sarah, additional, Usmani, Saad, additional, Grunwald, Michael, additional, Gerber, Jonathan, additional, Ghosh, Nilanjan, additional, Mccurdy, Lewis, additional, Fasan, Omotayo, additional, Ai, Jing, additional, Avalos, Belinda, additional, and Copelan, Edward, additional

Published
2016
Full Text
View/download PDF

215. Distribution of Cytogenetic Abnormalities in African American Multiple Myeloma Patients May be Unique for Different Geographic Regions

Author

Bhutani, Manisha, primary, Patel, Preeya, additional, Robinson, Myra M, additional, Bose, Rupali, additional, Madden, Kyle, additional, Eddy, Jill, additional, Roth, Candice G, additional, Symanowski, James, additional, Cogdill, Tammy, additional, Robinson, Jordan, additional, Avalos, Belinda R, additional, Copelan, Edward A., additional, and Usmani, Saad Z, additional

Published
2015
Full Text
View/download PDF

217. 106 - Survival Trends after Allogeneic Hematopoietic Cell Transplant (HCT) in Children Less Than One-Year-Old (Infants)

Author

Parikh, Suhag, Ahn, Kwang Woo, Sahr, Natasha, Zhu, Xiaochun, Abraham, Allistair, Auletta, Jeffery J., Chhabra, Saurabh, Copelan, Edward A., Dvorak, Christopher C., Fretham, Caitrin, Gadalla, Shahinaz M., Gale, Robert Peter, Gergis, Usama, Heimatti, Peiman, Hildebrandt, Gerhard C., Keating, Amy K., Myers, Kasiani C., Savani, Bipin N., Shah, Niketa C., Pasquini, Marcelo C., and Satwani, Prakash

Published
2018
Full Text
View/download PDF

218. Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days.

Author

Khouri, Jack, Rybicki, Lisa, Majhail, Navneet, Kalaycio, Matt, Copelan, Edward, Pohlman, Brad, Hill, Brian, Dean, Robert, Lazaryan, Aleksandr, Hamilton, Betty, Andresen, Steven, Sobecks, Ronald, Bolwell, Brian, and Liu, Hien

Abstract

Abstract: Background: Peripheral blood progenitor cell (PBPC) mobilization with chemotherapy in addition to Granulocyte‐Colony Stimulating Factor (G‐CSF) improves cell collection compared to G‐CSF alone; however, it is associated with increased risk of neutropenic fever (NF). Methods: We analyzed risk factors for post‐priming NF and NF association with autologous stem cell transplant outcomes. Between 1998 and 2008, 593 adult patients with lymphoma underwent PBPC mobilization with etoposide and G‐CSF. Results: Median age was 51 years (range 18–77) and 372 (63%) were male. Diagnoses were 457 (77%) non‐Hodgkin lymphoma and 136 (23%) Hodgkin lymphoma. Of 554 (93%) transplanted patients, majority were in complete or partial remission at time of transplant (88%). Overall, 141 (24%) patients were hospitalized for NF. Nine patients (6%) had bacteremia, 4 (3%) had pneumonia, 2 (<1%) had herpes simplex viral infections, and the remaining 126 (90%) had no identified infection source. NF patients had lower likelihood of proceeding to transplant (86% vs. 96%, P < .001), lower CD34+ cell dose collection (median 7.23 × 106 CD34+ cells/kg vs. 8.98 × 106 CD34+ cells/kg, P = .002), and were more likely to require > 4 days of apheresis (48% vs. 37%, P < .001). NF was associated with a higher 30‐day readmission rate following transplant hospitalization (17% vs. 9%, P = .012). Conclusion: NF during etoposide priming is associated with lower likelihood of proceeding to transplant, lower CD34+ cell dose collection, more apheresis days required for collection and a higher 30‐day readmission rate following transplant discharge. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

219. Successful Hematopoietic Stem Cell Transplantation Following a Cyclophosphamide-Containing Preparative Regimen with Concomitant Phenobarbital Administration

Author

Weber, Catherine, Kasberg, Heather, and Copelan, Edward

Subjects
Article Subject
Abstract

Cyclophosphamide is an immunosuppressive agent and an anticancer prodrug which requires bioactivation catalyzed primarily by cytochrome P450 enzymes in order to be transformed into its active alkylating compounds. Concomitant administration of drugs known to inhibit or induce this enzyme system is a clinical concern. Herein, we present the case of a chronically ill 21-year-old patient who received high-dose cyclophosphamide, equine antithymocyte globulin (eATG), and total body irradiation (TBI) followed by an allogeneic hematopoietic stem cell transplant (HSCT) for severe aplastic anemia. Throughout her hospitalization, she continued to receive quadruple anticonvulsant therapy including phenobarbital for her long-standing seizure history. The preparative regimen was tolerated well aside from a hypersensitivity reaction to eATG, and minimal cyclophosphamide-related toxicities. Safe and effective administration of high-dose cyclophosphamide was possible with multidisciplinary care consisting of physician, nursing, pharmacy, neurology consultation, as well as social work and case management.

Published
2012
Full Text
View/download PDF

221. Effect of Immunomodulatory Drugs (IMiDs) on Immune Effectors after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma

Author

Foureau, David M, Bhutani, Manisha, Zhang, Qing, Robinson, Myra M, Wynn, Adina, Steuerwald, Nury M, Druhan, Lawrence J, Guo, Fei, Rigby, Katherine, Turner, Mitchell, Friend, Reed, Atrash, Shebli, Sprouse, Chelsea, Ndiaye, Ami, Symanowski, James T, Avalos, Belinda Rene, Copelan, Edward A, Voorhees, Peter M., and Usmani, Saad Z

Published
2017
Full Text
View/download PDF

223. Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer

Author

Hamilton, Betty Ky, primary, Rybicki, Lisa, additional, Abounader, Donna, additional, Andresen, Steven, additional, Kalaycio, Matt, additional, Sobecks, Ronald, additional, Pohlman, Brad, additional, Hanna, Rabi, additional, Dean, Robert, additional, Liu, Hien, additional, Hill, Brian, additional, Bolwell, Brian, additional, and Copelan, Edward, additional

Published
2015
Full Text
View/download PDF

225. Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation

Author

Copelan, Edward A., primary, Avalos, Belinda R., additional, Ahn, Kwang Woo, additional, Zhu, Xiaochun, additional, Gale, Robert Peter, additional, Grunwald, Michael R., additional, Hamadani, Mehdi, additional, Hamilton, Betty K., additional, Hale, Gregory A., additional, Marks, David I., additional, Waller, Edmund K., additional, Savani, Bipin N., additional, Costa, Luciano J., additional, Ramanathan, Muthalagu, additional, Cahn, Jean-Yves, additional, Khoury, H. Jean, additional, Weisdorf, Daniel J., additional, Inamoto, Yoshihiro, additional, Kamble, Rammurti T., additional, Schouten, Harry C., additional, Wirk, Baldeep, additional, Litzow, Mark R., additional, Aljurf, Mahmoud D., additional, van Besien, Koen W., additional, Ustun, Celalettin, additional, Bolwell, Brian J., additional, Bredeson, Christopher N., additional, Fasan, Omotayo, additional, Ghosh, Nilanjan, additional, Horowitz, Mary M., additional, Arora, Mukta, additional, Szer, Jeffrey, additional, Loren, Alison W., additional, Alyea, Edwin P., additional, Cortes, Jorge, additional, Maziarz, Richard T., additional, Kalaycio, Matt E., additional, and Saber, Wael, additional

Published
2015
Full Text
View/download PDF

227. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes

Author

Saunthararajah, Yogen, primary, Sekeres, Mikkael, additional, Advani, Anjali, additional, Mahfouz, Reda, additional, Durkin, Lisa, additional, Radivoyevitch, Tomas, additional, Englehaupt, Ricki, additional, Juersivich, Joy, additional, Cooper, Kathleen, additional, Husseinzadeh, Holleh, additional, Przychodzen, Bartlomiej, additional, Rump, Matthew, additional, Hobson, Sean, additional, Earl, Marc, additional, Sobecks, Ronald, additional, Dean, Robert, additional, Reu, Frederic, additional, Tiu, Ramon, additional, Hamilton, Betty, additional, Copelan, Edward, additional, Lichtin, Alan, additional, Hsi, Eric, additional, Kalaycio, Matt, additional, and Maciejewski, Jaroslaw, additional

Published
2015
Full Text
View/download PDF

228. Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee

Author

Jimenez, Antonio M., Wang, Trent, de Lima, Marcos, Komanduri, Krishna V, Kebriaei, Partow, Litzow, Mark, Bhatt, Vijaya Raj, Baron, Frédéric, Saad, Ayman, Khera, Nandita, Maakaron, Joseph, Murthy, Hemant S., Copelan, Edward A, Defilipp, Zachariah, Bredeson, Christopher, Martino, Rodrigo, Krem, Maxwell, Nishihori, Taiga, Zhang, Mei-Jie, Weisdorf, Daniel J., Chen, Karen, and Saber, Wael

Abstract

de Lima: Celgene: Research Funding; Pfizer: Other: Personal fees, advisory board, Research Funding; BMS: Other: Personal Fees, advisory board; Incyte: Other: Personal Fees, advisory board; Kadmon: Other: Personal Fees, Advisory board. Komanduri:Kiadis: Consultancy; Takeda: Consultancy; Celgene: Consultancy; Atara: Consultancy, Membership on an entity's Board of Directors or advisory committees; Adaptimmune: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kite/Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees. Kebriaei:Ziopharm: Other: Research Support; Jazz: Consultancy; Kite: Other: Served on advisory board; Amgen: Other: Research Support; Novartis: Other: Served on advisory board; Pfizer: Other: Served on advisory board. Bhatt:National Marrow Donor Program: Research Funding; Rigel Pharmaceuticals: Other; Jazz: Research Funding; Agios: Other: Personal Fees; Incyte: Other: Personal Fees, Research Funding; Takeda: Other: Personal Fees; Partner Therapeutics: Other: Personal Fees; Pfizer: Other, Research Funding; CSL Behring: Other; Tolero Pharmaceuticals: Research Funding; Oncoceutics: Other: Drug support for a trial; Partnership for health analytic research, LLC: Other: Personal Fees; Omeros: Other: Personal Fees; Abbvie: Other: Personal Fees, Research Funding. Saad:Orcabio: Other: research support; Kadmon: Other: research support; Amgen: Other: research support; Incyte Pharmaceuticals: Other: Personal Fees; Magenta Therapeutics: Other: Personal Fees. Copelan:Amgen: Membership on an entity's Board of Directors or advisory committees. Defilipp:Incyte: Research Funding; Regimmune: Research Funding; Syndax Pharmaceuticals: Consultancy. Nishihori:Karyopharm: Other: Research support to institution; Novartis: Other: Research support to institution. Weisdorf:Incyte: Research Funding; FATE Therapeutics: Consultancy.

Published
2020
Full Text
View/download PDF

229. Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/ Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial

Author

Advani, Anjali S., primary, Elson, Paul, additional, Kalaycio, Matt E., additional, Mukherjee, Sudipto, additional, Gerds, Aaron T., additional, Hamilton, Betty K., additional, Hobson, Sean, additional, Smith, Arian, additional, Rush, Mary Lynn, additional, Bogati, Samjhana, additional, Biggins, Monique, additional, Hsi, Eric D., additional, Duong, Hien K., additional, Copelan, Edward A., additional, Reu, Frederic J., additional, Saunthararajah, Yogen, additional, Nazha, Aziz, additional, Makishima, Hideki, additional, Przychodzen, Bartlomiej, additional, Dienes, Brittney, additional, Maciejewski, Jaroslaw P., additional, Carew, Jennifer S, additional, Carraway, Hetty E., additional, and Sekeres, Mikkael A., additional

Published
2014
Full Text
View/download PDF

230. Impact of Day 28 Absolute Lymphocyte Count on Outcome of Adult Patients with Acute Myeloid Leukemia

Author

Bumma, Naresh, primary, Ai, Jing, additional, Jia, Xuefei, additional, Hobson, Sean, additional, Abounader, Donna, additional, Sekeres, Mikkael A., additional, Kalaycio, Matt E., additional, Sobecks, Ron, additional, Gerds, Aaron, additional, Hamilton, Betty K., additional, Mukherjee, Sudipto, additional, Carraway, Hetty E., additional, Tench, Shawnda, additional, Copelan, Edward A., additional, and Advani, Anjali S., additional

Published
2014
Full Text
View/download PDF

231. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA‐identical sibling donor allogeneic hematopoietic cell transplantation

Author

Hamilton, Betty K., primary, Rybicki, Lisa, additional, Dean, Robert, additional, Majhail, Navneet S., additional, Haddad, Housam, additional, Abounader, Donna, additional, Hanna, Rabi, additional, Sobecks, Ronald, additional, Duong, Hien, additional, Hill, Brian T., additional, Copelan, Edward, additional, Bolwell, Brian, additional, and Kalaycio, Matt, additional

Published
2014
Full Text
View/download PDF

232. Sibling versus Unrelated Donor Allogeneic Hematopoietic Cell Transplantation for CML: Refined HLA-matching shows more GVHD but not less relapse

Author

Weisdorf, Daniel J., Nelson, Gene, Lee, Stephanie J, Haagenson, Michael, Spellman, Stephen, Antin, Joseph H, Bolwell, Brian, Cahn, Jean-Yves, Cervantes, Francisco, Copelan, Edward, Gale, Robert, Gratwohl, Alois, Khoury, H. Jean, McCarthy, Philip, Marks, David I, Szer, Jeff, Woolfrey, Ann, Cortes-Franco, Jorge, Horowitz, Mary M, and Arora, Mukta

Subjects
Adult, Male, Histocompatibility Testing, Siblings, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Graft vs Leukemia Effect, Article, Disease-Free Survival, HLA Antigens, Recurrence, Histocompatibility, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Living Donors, Humans, Transplantation, Homologous, Female, Prospective Studies, Proportional Hazards Models, Retrospective Studies
Abstract

Unrelated donor (URD) hematopoietic cell transplantation (HCT) can eradicate chronic myelogenous leukemia (CML). It has been postulated that greater donor-recipient histoincompatibility can augment the graft-versus-leukemia (GVL) effect. We previously reported similar, but not equivalent, outcomes of URD versus sibling donor HCT for CML using an older, less precise classification of HLA matching. Here, we used our recently refined HLA-matching classification, which is suitable for interpretation when complete allele-level typing is unavailable, to reanalyze outcomes of previous HCT for CML. We found that using our new matching criteria identifies substantially more frequent mismatching than older, less precise "6 of 6 antigen-matched" URD-HCT. Under the new criteria, only 37% of those previously deemed "HLA- matched" were HLA well matched, and 44% were partially matched. Using our refined matching criteria confirms the greater risk of graft failure in partially matched or mismatched URD-recipient pairs compared with either sibling or well-matched URD-recipient pairs. Acute and chronic graft-versus-host disease (aGVHD, cGVHD) are significantly more frequent with all levels of recategorized URD HLA matching. Importantly, overall survival (OS) and leukemia-free survival (LFS) remain significantly worse after URD-HCT at any matching level. No augmented GVL effect accompanied URD HLA mismatch. Compared with sibling donor transplants, we observed only marginally increased (not statistically significant) risks of relapse in well-matched, partially matched, and mismatched URD-HCT. These data confirm the applicability of revised HLA-matching scheme in analyzing retrospective data sets when fully informative, allele-level typing is unavailable. In this analysis, greater histoincompatibility can augment GVHD, but does not improve protection against relapse; thus the best donor remains the most closely matched donor.

Published
2009

234. 84 - Impact of Higher-Dose Total Body Irradiation Conditioning on Outcome of an Allogeneic Hematopoietic Cell Transplant (HCT) in the Modern Era

Author

Sabloff, Mitchell, Wang, Tao, Zhu, Xiaochun, Artz, Andrew S., Adekola, Kehinde, Abraham, Allistair, Auletta, Jeffery J., Battiwalla, Minoo, Beitinjaneh, Amer, Bredeson, Christopher N., Bufarull, Rodrigo Martino, Cahn, Jean-Yves, Cerny, Jan, Chhabra, Saurabh, Copelan, Edward A., Daly, Andrew, Dias, Ajoy, Diaz, Miguel Angel, Freytes, Cesar O., Gale, Robert Peter, Ganguly, Siddhartha, Hale, Gregory A., Hamilton, Betty Ky, Hashmi, Shahrukh K., Hematti, Peiman, Hildebrandt, Gerhard C., Holmberg, Leona A., Hong, Sanghee, Kekre, Natasha, Lazarus, Hillard M., Lazaryan, Aleksandr, Luger, Selina M., Muffly, Lori, Nagler, Arnon, Nishihori, Taiga, Norkin, Maxim, Olsson, Richard, Perales, Miguel-Angel, Rashidi, Armin, Romee, Rizwan, Saad, Ayman, Seo, Sachiko, Ulrickson, Matthew L., Ustun, Celalettin, Wirk, Baldeep M., Woolfrey, Ann E., Yared, Jean, Pasquini, Marcelo C., and Mineishi, Shin

Published
2017
Full Text
View/download PDF

242. Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations

Author

Giralt, Sergio, primary, Costa, Luciano, additional, Schriber, Jeffrey, additional, DiPersio, John, additional, Maziarz, Richard, additional, McCarty, John, additional, Shaughnessy, Paul, additional, Snyder, Edward, additional, Bensinger, William, additional, Copelan, Edward, additional, Hosing, Chitra, additional, Negrin, Robert, additional, Petersen, Finn Bo, additional, Rondelli, Damiano, additional, Soiffer, Robert, additional, Leather, Helen, additional, Pazzalia, Amy, additional, and Devine, Steven, additional

Published
2014
Full Text
View/download PDF

243. Risk for Developing Myelodysplastic Syndromes in Prostate Cancer Patients Definitively Treated With Radiation

Author

Mukherjee, Sudipto, primary, Reddy, Chandana A., additional, Ciezki, Jay P., additional, Abdel-Wahab, May, additional, Tiu, Ramon V., additional, Copelan, Edward, additional, Advani, Anjali A., additional, Saunthararajah, Yogen, additional, Paulic, Katarina, additional, Hobson, Sean, additional, Maciejewski, Jaroslaw P., additional, Bolwell, Brian J., additional, Kalaycio, Matt, additional, Dreicer, Robert, additional, Klein, Eric A., additional, and Sekeres, Mikkael A., additional

Published
2014
Full Text
View/download PDF

244. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI

Author

Copelan, Edward A., primary, Hamilton, Betty K., additional, Avalos, Belinda, additional, Ahn, Kwang Woo, additional, Bolwell, Brian J., additional, Zhu, Xiaochun, additional, Aljurf, Mahmoud, additional, van Besien, Koen, additional, Bredeson, Christopher, additional, Cahn, Jean-Yves, additional, Costa, Luciano J., additional, de Lima, Marcos, additional, Gale, Robert Peter, additional, Hale, Gregory A., additional, Halter, Joerg, additional, Hamadani, Mehdi, additional, Inamoto, Yoshihiro, additional, Kamble, Rammurti T., additional, Litzow, Mark R., additional, Loren, Alison W., additional, Marks, David I., additional, Olavarria, Eduardo, additional, Roy, Vivek, additional, Sabloff, Mitchell, additional, Savani, Bipin N., additional, Seftel, Matthew, additional, Schouten, Harry C., additional, Ustun, Celalettin, additional, Waller, Edmund K., additional, Weisdorf, Daniel J., additional, Wirk, Baldeep, additional, Horowitz, Mary M., additional, Arora, Mukta, additional, Szer, Jeff, additional, Cortes, Jorge, additional, Kalaycio, Matt E., additional, Maziarz, Richard T., additional, and Saber, Wael, additional

Published
2013
Full Text
View/download PDF

245. Providing Personalized Prognostic Information for Adult Leukemia Survivors

Author

Lee, Stephanie J., primary, Storer, Barry, additional, Wang, Hailin, additional, Lazarus, Hillard M., additional, Waller, Edmund K., additional, Isola, Luis M., additional, Klumpp, Thomas R., additional, Umejiego, John Bosco C., additional, Savani, Bipin N., additional, Loren, Alison W., additional, Cairo, Mitchell S., additional, Camitta, Bruce M., additional, Cutler, Corey S., additional, George, Biju, additional, Jean Khoury, H., additional, Marks, David I., additional, Rizzieri, David A., additional, Copelan, Edward A., additional, Gupta, Vikas, additional, Liesveld, Jane L., additional, Litzow, Mark R., additional, Miller, Alan M., additional, Schouten, Harry C., additional, Gale, Robert Peter, additional, Cahn, Jean-Yves, additional, and Weisdorf, Daniel J., additional

Published
2013
Full Text
View/download PDF

246. Sibling versus Unrelated Donor Allogeneic Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia: Refined HLA Matching Reveals More Graft-versus-Host Disease but not Less Relapse

Author

Weisdorf, Daniel J., Nelson, Gene, Lee, Stephanie J., Haagenson, Michael, Spellman, Stephen, Antin, Joseph H., Bolwell, Brian, Cahn, Jean-Yves, Cervantes, Francisco, Copelan, Edward, Gale, Robert, Gratwohl, Alois, Khoury, H. Jean, McCarthy, Philip, Marks, David I., Szer, Jeff, Woolfrey, Ann, Cortes-Franco, Jorge, Horowitz, Mary M., and Arora, Mukta

Published
2009
Full Text
View/download PDF

247. Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research

Author

Foran, James M., primary, Pavletic, Steven Z., additional, Logan, Brent R., additional, Agovi-Johnson, Manza A., additional, Pérez, Waleska S., additional, Bolwell, Brian J., additional, Bornhäuser, Martin, additional, Bredeson, Christopher N., additional, Cairo, Mitchell S., additional, Camitta, Bruce M., additional, Copelan, Edward A., additional, Dehn, Jason, additional, Gale, Robert P., additional, George, Biju, additional, Gupta, Vikas, additional, Hale, Gregory A., additional, Lazarus, Hillard M., additional, Litzow, Mark R., additional, Maharaj, Dipnarine, additional, Marks, David I., additional, Martino, Rodrigo, additional, Maziarz, Richard T., additional, Rowe, Jacob M., additional, Rowlings, Philip A., additional, Savani, Bipin N., additional, Savoie, Mary Lynn, additional, Szer, Jeffrey, additional, Waller, Edmund K., additional, Wiernik, Peter H., additional, and Weisdorf, Daniel J., additional

Published
2013
Full Text
View/download PDF

249. Impact of allogeneic hematopoietic stem cell transplant (HSCT) on patients harboring the spliceosome mutation SRSF2.

Author

Hamilton, Betty Ky, primary, Tabarroki, Ali, additional, Elson, Paul, additional, Hasrouni, Edy, additional, Visconte, Valeria, additional, Tench, Shawnda, additional, Kalaycio, Matt E., additional, Sekeres, Mikkael A., additional, Sobecks, Ronald M., additional, Duong, Hien Kim, additional, Hill, Brian Thomas, additional, Bolwell, Brian James, additional, Copelan, Edward Alan, additional, and Tiu, Ramon Velasquez, additional

Published
2013
Full Text
View/download PDF

250. Allogeneic Hematopoietic Cell Transplantation for Fanconi Anemia in Patients With Pretransplantation Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia

Author

Ayas, Mouhab, primary, Saber, Wael, additional, Davies, Stella M., additional, Harris, Richard E., additional, Hale, Gregory A., additional, Socie, Gerard, additional, LeRademacher, Jennifer, additional, Thakar, Monica, additional, Deeg, H. Joachim J., additional, Al-Seraihy, Amal, additional, Battiwalla, Minoo, additional, Camitta, Bruce M., additional, Olsson, Richard, additional, Bajwa, Rajinder S., additional, Bonfim, Carmem M., additional, Pasquini, Ricardo, additional, MacMillan, Margaret L., additional, George, Biju, additional, Copelan, Edward A., additional, Wirk, Baldeep, additional, Al Jefri, Abdullah, additional, Fasth, Anders L., additional, Guinan, Eva C., additional, Horn, Biljana N., additional, Lewis, Victor A., additional, Slavin, Shimon, additional, Stepensky, Polina, additional, Bierings, Marc, additional, and Gale, Robert Peter, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results